% | $
Quotes you view appear here for quick access.


  • laujhawj laujhawj Dec 4, 2010 2:39 PM Flag

    Let's Hope We Hear CHA & ACT Announcing...

    Further and more advanced research on their joint blood endeavor, now that 2+ years have come to pass since they came together to tackle the blood and platelette issues...

    And Dr. Lanza was not tootin' for his South Korean colleagues --- when he said S.Korea is "one of the wealthiest AND BOASTS THE HIGHEST SCIENTIFIC LIERACY IN THE WORLD" --- since I read about 3-4 years ago, that South Koreans were, back then and likely today still (although those in Japan and one or two northern European countries like Norway, Sweden, etc. may correct me), the ONLY country that virtually every household had broad band technology where fast downloading, full-screen, hi-definition pictures were the norm (as opposed to us having 5x7 inch YouTube like screens)...

    So the South Koreans are indeed, have been for close to 10 years now, among the top five most extremely technologically advanced societies, in computational, telecommunications, and biological sciences...


    Leading Korean Biotech Company & Advanced Cell Technology Form JVMonday December 1,

    “We are very excited about forming this joint venture with this company recognized throughout Asia as a leader in stem cell technology,” stated William M. Caldwell IV, Chairman and CEO of ACT. “CHA Biotech will provide much needed technical and financial resources to our efforts to commercialize an O Negative stem cell derived blood product. Dr Lanza and his team will work with the new company to move this program into the clinic.”

    “Stem cell research is increasingly becoming an international collaborative effort,” said Dr. Lanza, ACT’s Chief Scientific Officer. “This venture represents the accelerating globalization of biotechnology. South Korea is one of the wealthiest countries in Asia and boasts the highest scientific literacy in the world. It is also home to world leaders in technologically advanced goods, including companies such as Samsung, LG and Hyundai. We are excited to be part of this growing international effort based on cooperation between the biotechnology industry, academia, and research institutes.”

    ”We believe ACT’s hemangioblast cells have great potential in addressing many unmet medical needs through the use of stem cell technology,” said Dr. Hyung-Min Chung, CEO of CHA Biotech.. “We look forward to working closely with them to commercialize this promising technology. Similarly, we look forward to working with ACT on other stem cell technologies and increase the areas of cooperation between the two companies.”


    CHA Biotech presently operates the largest stem cell research institute in Korea occupying a modern 130,000 sq. ft., state-of-the-art facility staffed with over 20 professors and involving 130 of the most prominent research scientists. The Company also successfully operates CHA i-Cord, a cord blood bank, and a mobile healthcare unit called CHA Paramedic Service, both of which were rated #1 in consumer reliability surveys in Korea. As part of its global business strategy, CHA Biotech expanded its operations to the United States in 2002 with the opening of CHA Fertility Center in Los Angeles followed by the 2005 acquisition of Hollywood Presbyterian Medical Center, a 434-bed general, acute-care hospital also located in LA.

    SortNewest  |  Oldest  |  Most Replied Expand all replies